The Toronto-Dominion Bank (NYSE:TD) RBC Capital Markets Canadian Bank CEO Conference January 9, 2024 1:20 PM ET Company Participants Bharat Masrani - Group President and Chief Executive Officer Conference Call Participants Darko Mihelic - RBC Capital Markets Darko Mihelic Okay. Great. Thank you. We'll start the next session with, TD Bank. I'm pleased to have Bharat Masrani on the stage. Thank you for joining us today, Bharat. Bharat Masrani Nice to be here, Darko. Happy New Year to you and to all of you. Go ...

Danaher Corporation (NYSE:DHR) 42nd Annual J.P. Morgan Healthcare Conference January 9, 2024 2:15 PM ET Company Participants Rainer Blair - President and Chief Executive Officer Conference Call Participants Rachel Vatnsdal - JPMorgan Rachel Vatnsdal Good afternoon, everyone. This is Rachel Vatnsdal from the Life Science Tools and Diagnostics team here at JP Morgan. Thank you for coming to the Danaher presentation. This will be a 40-minute session as we typically do roughly 20 minutes of a presentation foll ...

Illumina, Inc. (NASDAQ:ILMN) J.P. Morgan 42nd Annual Healthcare Conference January 9, 2024 12:00 PM ET Company Participants Jacob Thaysen - CEO Joydeep Goswami - CFO, Chief Strategy and Corporate Development Officer Conference Call Participants Rachel Vatnsdal - J.P. Morgan Rachel Vatnsdal Perfect. Good morning, everyone. This is Rachel Vatnsdal with the Life Science Tools and Diagnostics team, I'm here with Illumina up on stage. So as these sessions are, it's going to be 40 minutes, roughly 20 minutes of p ...

BioNTech SE (NASDAQ:BNTX) 42nd Annual J.P. Morgan Healthcare Conference January 9, 2024 12:00 PM ET Company Participants Ugur Sahin - CEO Ryan Richardson - Chief Strategy Officer Conference Call Participants Jess Fye - J.P. Morgan Jess Fye Great. Good morning, everyone. My name is Jess Fye. I am a Senior Biotech Analyst at J.P. Morgan, and we’re continuing the conference today with BioNTech. I am joined by the company's CEO, Dr. Ugur Sahin. He is going to give a presentation on the company and then we are g ...

Novartis AG (NYSE:NVS) 2024 J.P. Morgan 42nd Annual Healthcare Conference Call January 8, 2024 9:00 AM ET Company Participants Vas Narasimhan - Chief Executive Officer Conference Call Participants Richard Vosser - J.P. Morgan Richard Vosser Welcome to the Novartis presentation at the 42nd J.P. Morgan Healthcare Conference. I'm Richard Vosser, European Pharma Analyst with J.P. Morgan. It's my great pleasure to welcome Vas Narasimhan, the CEO of Novartis today. Before I hand over to Vas, I'll just everyone; w ...

GSK plc (NYSE:GSK) 42nd Annual JP Morgan Healthcare Conference January 9, 2024 10:30 AM ET Company Participants Emma Walmsley - Chief Executive Officer Luke Miels - Chief Commercial Officer Tony Wood - Chief Scientific Officer Conference Call Participants James Gordon - JPMorgan James Gordon Good morning. I'm James Gordon, JPMorgan European pharma and biotech analyst. And today, I've got the pleasure of introducing the GSK presentation. You're going to hear from GSK CEO, Emma Walmsley. Thanks a lot for join ...

Novo Nordisk A/S (NVO) J.P. Morgan 42nd Annual Healthcare Conference January 9, 2024 12:45 PM ET Company Participants Lars Fruergaard Jorgensen - President & Chief Executive Officer Conference Call Participants Richard Vosser - JPMorgan Richard Vosser Welcome to the Novo Nordisk session at the 2024 JPMorgan Healthcare Conference. I'm Richard Vosser, European pharma analyst with JPMorgan, and it's my great pleasure to welcome the CEO of Novo, Lars Fruergaard Jorgensen to the conference for the first time. So ...

Thermo Fisher Scientific, Inc. (NYSE:TMO) 42nd Annual J.P. Morgan Healthcare Conference January 9, 2023 11:15 AM ET Company Participants Marc Casper – Chief Executive Officer Conference Call Participants Rachel Vatnsdal – J.P. Morgan Rachel Vatnsdal Perfect. Good morning everyone. This is Rachel Vatnsdal from the Life Science Tools and Diagnostics team here at J.P. Morgan. I'm joined on stage by Marc Casper, CEO of Thermo Fisher. So as we typically do, this is going to be a 40 minute session. First of it, h ...

Agilent Technologies, Inc. (NYSE:A) J.P. Morgan 42nd Annual Healthcare Conference January 9, 2024 12:45 PM ET Company Participants Mike McMullen - President & Chief Executive Officer Bob McMahon - Chief Financial Officer Conference Call Participants Rachel Vatnsdal - JPMorgan Rachel Vatnsdal Hi. Good morning, everyone. This is Rachel Vatnsdal with the Life Science Tools and Diagnostics team here at JPMorgan. I'm joined by the Agilent management team on stage as these sessions typically are, it's 40 minutes, ...

Summary of Cigna Group's J.P. Morgan 42nd Annual Healthcare Conference Company Overview - **Company**: Cigna Group (NYSE: CI) - **Participants**: - David Cordani - President, Chief Executive Officer & Chair - Eric Palmer - Chief Executive Officer & President, Evernorth - **Date**: January 9, 2024 Key Points 1. Strong Performance in 2023 - Cigna reported a strong performance in 2023, continuing a track record of organic growth across various operating platforms, including PBM, commercial business, international benefits, and government benefits [3][4][8] 2. EPS Guidance for 2024 - The company reiterated its EPS outlook for 2024 at least $28, which is above the high end of its growth algorithm of 10% to 13% EPS growth over time [5][8] 3. Capital-Light Business Model - Cigna operates a capital-light, service-oriented portfolio, allowing for quick conversion of operating cash flow to deployable cash flow, providing strategic advantages in a fluid business environment [6][8] 4. Innovations in Pharmacy and Healthcare - Cigna is focusing on pharmacy innovations, particularly in pharmacological advancements like GLP-1s, and aims to optimize clinical protocols for better value for patients and financiers [7][8] 5. Government Benefits Business - Cigna is committed to expanding its capabilities in the government services portfolio, including Medicare and Medicaid, and sees growth potential in this area [14][15] 6. Evernorth's Growth and Strategy - Evernorth is positioned to reduce fragmentation in healthcare delivery and improve health outcomes through partnerships, such as with VillageMD, focusing on risk-bearing and performance-based models [18][19][21] 7. Market Trends and Client Needs - There is a trend of point solution fatigue among employers, leading to a demand for more integrated healthcare solutions and precision in care delivery [40][70] 8. Retention and Growth in PBM - Cigna's PBM business is experiencing strong retention and growth, with innovations in product offerings and a focus on client satisfaction [25][26][27] 9. Legislative Environment for PBMs - The PBM industry is under scrutiny, with potential legislative changes expected. Cigna is proactively engaging with officials to ensure transparency and value delivery [62][64][66] 10. Biosimilars and Market Adoption - Cigna anticipates increased adoption of biosimilars, particularly for high-cost medications like HUMIRA, which is expected to improve affordability for clients [58][60][61] 11. Commercial Business Outlook - Cigna's commercial business is expected to grow, particularly in the Select segment, despite anticipated softening in the employment landscape [67][70][71] Additional Insights - Cigna emphasizes the importance of aligning incentives in value-based care arrangements, which can involve shared risk with manufacturers or providers [46][48] - The company is adapting to market changes, including the potential resurgence of mail-order pharmacy services due to evolving consumer preferences [54][57] This summary encapsulates the key insights and strategic directions discussed during the conference, highlighting Cigna's robust performance, innovative approaches, and proactive engagement in the healthcare landscape.